• Aucun résultat trouvé

Targeting of CXCR4+ Glioblastoma Initiating Cells with a retargeted oncolytic herpesvirus

N/A
N/A
Protected

Academic year: 2021

Partager "Targeting of CXCR4+ Glioblastoma Initiating Cells with a retargeted oncolytic herpesvirus"

Copied!
1
0
0

Texte intégral

(1)

TFIP

TFIP

Targeting of CXCR4

+

Glioblastoma Initiating Cells with a retargeted

oncolytic herpesvirus

Sánchez Gil Judit1, Lebrun Marielle1, Allegro Adrien1, Chevigné Andy2, Rogister Bernard3, Sadzot Dalvaux Catherine1.

1: Laboratory of Virology and Immunology,GIGA-I3, University of Liège.

2: Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health 3: Laboratory of Nervous System diseases and Therapy, GIGA-Neurosciences, University of Liège

Glioblastoma is the most common and aggressive primary brain tumor in adults. Surgical resection followed by radiotherapy and/or chemotherapy is the standard treatment. However, despite improvement of these treatments, glioblastoma patients have a poor prognosis, mainly due to recurrence. It has been shown in an orthotopic xenograft model that GBM cells can escape the tumor mass and specifically invade the subventricular zones (SVZ) of the adult brain. These cells have been shown to be CXCR4+ and to be attracted by CXCL12 secreted by the SVZ cells (Goffart, N. et al., Neuro-oncology, 2014, 17(1), 81-94). These cells are the only tumor cells able to initiate a tumor and thus show characteristics that identified them as Glioblastoma Initiating Cells (GIC). In addition, these cells, which are not removed with the surgical resection are more resistant to radiotherapy and are probably responsible for the recurrence.

Background

The aim of this project is to build an oncolytic HSV (oHSV) able to (1) target specifically the CXCR4+ GICs and to (2) induce their apoptosis.

Aim

These preliminary results suggest that the retargeted oHSV expressing gD fused to a nanobody specific to CXCR4 works correctly, being able to specifically infect CXCR4+ GBM cells. When armed with pnestin-sTRAIL, It is able to induce apoptosis in GBM cells in which the nestin promoter is active. This virus is currently under characterisation in neurospheres and its safety and efficacy will be soon evaluated in vivo in an orthotopic xenograft model.

Conclusions

Results

1. Targeting: modification of gD to target to CXCR4+ cells

2. Arming: introduction of a transgene coding for a soluble form of TRAIL

A gene coding for a soluble form of TRAIL driven by the nestin promoter has been further introduced in oHSV/gD-Nb.

Adapted from Khalid et al., 2004, 64: 3236-3242

The specificity and efficacy of the armed oHSV was evaluated by quantification of the viability of cells 72hpi (MOI:1) (MTT assay). The viability of HT1080 in which the nestin promoter is not active is not improved by sTRAIL demonstrating the specificity of the promotor.

TFIP

The capacity of oHSV/gD-Nb to infect only cells expressing CXCR4 has been analysed by infecting U87.CL5.CXCR4-or U87.NIH2.CXCR4+ and confirmed by qRT PCR (data not shown).

TFIP TFIP

The correct de-targeting of the modified oHSVs have been evaluated by infecting J1.1 cells (HSV resistant) J-HVEM+ and J-Nectin+ cells (kind gift of G. Campadelli-Fiume) with a

MOI of 1, 0,1 or 0,01 (72 hpi). CXCL12α oHSV/gD-CXCL12 Linker HA Nb Linker oHSV/gD-Nb oHSV/gD-WT

Adapted from Uchida et al; 2013

gD -WT gD -CX CL1 2 gD -Nb

An oHSV virus with a modified glycoprotein targeting CXCR4 has been created using the “en passant” technique described by Osterreider et al., 2006 (Karstentischer, Bet al., 2006, BioTechniques, 40(2),191-197):

• The gD domain required for the interaction with the natural receptors HVEM and Nectin) has been deleted or mutated respectively and replaced by either CXCL12 or a anti CXCR4-nanobody.

• Tyr 38 important for the interaction with Nectin has been mutated into Cyst. The oHSV/gD-Nb is efficiently detargeted while the gD-CXCL12 has reverted and is still able to infected Nectin+ cells

Modified from Goffart, N. et al., Neuro Oncol. 2015 Jan; 17(1): 81–94 Tumor mass Corpus callosum Subventricular Zone (CXCL12 secretion) CXCR4+ GBM cells U8 7. C L5 . CX CR 4-U8 7. N IH 2. CX CR 4+

24hpi 48hpi 72hpi

oHSV+gD-Nb

GBM Non GBM

When compared with the gD-WT that can induce mortality in all cell lines, the retargeted virus induces mortality only in CXCR4+ cells indicating that the retargeting of oHSV allows to specifically infect CXCR4+ cells.

CXCR4 pos. cells CXCR4 neg. cells

GBM cells viability is affected in GBM cells only if they are CXCR4 positive (Green arrow) while the virus could not infect GBM negative cells and

thereby doesn’t affect their viability (Red arrow)

P-nestin Hflt3 signal seq Furine pept.

Leu

Zipper TRAIL PS

Références

Documents relatifs

Competing Interests: The authors have read the journal's policy and the authors of this manuscript have the following competing interests: Maksym Kopanitsa and Nurudeen Afinowi

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des

The two subunits of the functional IL-22R complex, IL-22R1 and IL-10R2 were detected in the U87MG and the U118MG GBM cell lines both at mRNA (Fig. 1D and 1E) levels with a

The fact that stimulation of AP-1 occurs mainly at 1 μM and not at 10 μM fits with our in vivo results: no tumors were observed after 40 days when mice were grafted with 1

Our DEAD-box RNA helicases siRNA library screening in multiple human cell lines consistently identified three RNA helicases (DHX29, DHX35 and RIG-I) for which the knockdown

The other "falsifiable asser- tion" according to Anderson, is that "No one can give what he hasn't got." I'm sure Anderson does not quarrel with this statement —

Si nos sentiments parlent un jour, nous pourrons dire que ce jour-là sera aujourd’hui.. Chaque jour qui passe, chaque temps bousillé, écrasé, je pense

Thus, the number of SARS-CoV-2-associated deaths was similar to that of deaths associated with other viral respiratory infections between December 2019 and March 2020, and lower